Novavax’s COVID-flu combo vaccine shows strong immune response in trial
Nuvaxovid gained the U.S. approval last month after the FDA missed an April 1 target to approve the shot. The approval, however, limited its use to older adults and at-risk...
Nuvaxovid gained the U.S. approval last month after the FDA missed an April 1 target to approve the shot. The approval, however, limited its use to older adults and at-risk...
